Skip to main content
Erschienen in: Rheumatology International 1/2009

01.11.2009 | Original Article

DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects

verfasst von: Salima Belguith-Maalej, Hassen Hadj-Kacem, Neila Kaddour, Zouhir Bahloul, Hammadi Ayadi

Erschienen in: Rheumatology International | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases (AID) are caused by the loss of immunological tolerance against self-antigens. The deoxyribonuclease I (DNASE1) gene seems to participate in the genetic susceptibility of some AID. In fact, two mutations were reported among systemic lupus erythematosus (SLE) patients from Japan and Spain (the 172 A → T mutation (K5X) and the 46_72 deletion, respectively). The aim of our work was to evaluate the DNASE1 contribution in the genetic susceptibility of rheumatoid arthritis (RA, n = 151), Sjögren syndrome (SS, n = 55) and SLE (n = 34) in Tunisia. DNA from patients and healthy subjects (n = 232) were explored. Both reported mutations were absent among patient and control subjects. The DNASE1 exon2 sequence was analysed among 26 control subjects to identify new polymorphic variations that are possible. Five known SNPs were explored. The G/T transversion (rs8176927: R2S) was the most polymorphic functional nonsynonymous SNP. Using PCR-RFLP method, all DNAs were genotyped for rs8176927 for a case–control design. The statistical analysis showed no significant differences between patients and controls genotype data. In conclusion, our study showed, on the one hand, the absence of the K5X mutation and the 46_72 deletion in Tunisian patients affected with RA, SS and SLE and healthy subjects, and, on the other hand, the absence of association between the R2S polymorphism and the genetic susceptibility of RA, SS and SLE.
Literatur
1.
Zurück zum Zitat Yasuda T, Awazu S, Sato W et al (1990) Human genetically polymorphic deoxyribonuclease: purification, characterization, and multiplicity of urine deoxyribonuclease I. J Biochem 108:393–398PubMed Yasuda T, Awazu S, Sato W et al (1990) Human genetically polymorphic deoxyribonuclease: purification, characterization, and multiplicity of urine deoxyribonuclease I. J Biochem 108:393–398PubMed
2.
Zurück zum Zitat Rauch F, Polzar B, Stephan H et al (1997) Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptic elimination. J Cell Biol 137:909–923. doi:10.1083/jcb.137.4.909 CrossRefPubMed Rauch F, Polzar B, Stephan H et al (1997) Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptic elimination. J Cell Biol 137:909–923. doi:10.​1083/​jcb.​137.​4.​909 CrossRefPubMed
3.
Zurück zum Zitat Mannherz HG, Peitsch MC, Zanotti S et al (1995) A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 198:161–174PubMed Mannherz HG, Peitsch MC, Zanotti S et al (1995) A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 198:161–174PubMed
11.
Zurück zum Zitat Ter Borg EJ, Horst G, Hummel EJ et al (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term prospective study. Arthritis Rheum 33:634–643. doi:10.1002/art.1780330505 CrossRefPubMed Ter Borg EJ, Horst G, Hummel EJ et al (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term prospective study. Arthritis Rheum 33:634–643. doi:10.​1002/​art.​1780330505 CrossRefPubMed
17.
Zurück zum Zitat Simmonds MJ, Heward JM, Kelly MA et al (2002) A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves’ disease: comment on the article by Rood et al. Arthritis Rheum 46:3109–3110. doi:10.1002/art.10414 CrossRefPubMed Simmonds MJ, Heward JM, Kelly MA et al (2002) A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves’ disease: comment on the article by Rood et al. Arthritis Rheum 46:3109–3110. doi:10.​1002/​art.​10414 CrossRefPubMed
18.
Zurück zum Zitat Chakraborty P, Hadj Kacem H, Makni-Karray K et al (2003) The A/T mutation in exon 2 of the DNASE1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects. Arthritis Rheum 48:3297–3298. doi:10.1002/art.11318 CrossRefPubMed Chakraborty P, Hadj Kacem H, Makni-Karray K et al (2003) The A/T mutation in exon 2 of the DNASE1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects. Arthritis Rheum 48:3297–3298. doi:10.​1002/​art.​11318 CrossRefPubMed
20.
Zurück zum Zitat Balada E, Ordi-Ros J, Hernanz S et al (2002) DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew et al. Arthritis Rheum 46:1974–1976. doi:10.1002/art.10349 CrossRefPubMed Balada E, Ordi-Ros J, Hernanz S et al (2002) DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew et al. Arthritis Rheum 46:1974–1976. doi:10.​1002/​art.​10349 CrossRefPubMed
23.
Zurück zum Zitat Kaplan G (1991) Syndrome de Gougerot-Sjögren. In: Kahn MF, Peltier AP, Meyer O, Piette JC (eds) Les maladies systémique, 2nd edn. Flammarion Médecine-Sciences, Paris, pp 499–544 Kaplan G (1991) Syndrome de Gougerot-Sjögren. In: Kahn MF, Peltier AP, Meyer O, Piette JC (eds) Les maladies systémique, 2nd edn. Flammarion Médecine-Sciences, Paris, pp 499–544
24.
25.
Zurück zum Zitat Kawazaki E (1990) Sample preparation from blood, cells and other fluids. In: Innis M, Gelffand D, Snisky G, White T (eds) PCR protocols. A guide to methods and application, 2nd edn. Academic Press, San Diego, pp 146–152 Kawazaki E (1990) Sample preparation from blood, cells and other fluids. In: Innis M, Gelffand D, Snisky G, White T (eds) PCR protocols. A guide to methods and application, 2nd edn. Academic Press, San Diego, pp 146–152
29.
Zurück zum Zitat Benucci M, Saviola G, Baiardi P et al (2008) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol 27:91–95. doi:10.1007/s10067-007-0728-5 CrossRefPubMed Benucci M, Saviola G, Baiardi P et al (2008) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol 27:91–95. doi:10.​1007/​s10067-007-0728-5 CrossRefPubMed
30.
Zurück zum Zitat Nardi N, Brito-Zerón P, Ramos-Casals M et al (2006) Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome, prevalence and clinical significance in 335 patients. Clin Rheumatol 25:341–346. doi:10.1007/s10067-005-0059-3 CrossRefPubMed Nardi N, Brito-Zerón P, Ramos-Casals M et al (2006) Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome, prevalence and clinical significance in 335 patients. Clin Rheumatol 25:341–346. doi:10.​1007/​s10067-005-0059-3 CrossRefPubMed
31.
Zurück zum Zitat Rechlin M (1997) Systemic rheumatic diseases: undifferentiated connective tissue disease, overlap syndromes, and mixed connective tissue disease. In: Koopman WJ (ed) Arthritis and allied conditions a text book of rheumatology. William & Wilkins, Baltimore, pp 1445–1454 Rechlin M (1997) Systemic rheumatic diseases: undifferentiated connective tissue disease, overlap syndromes, and mixed connective tissue disease. In: Koopman WJ (ed) Arthritis and allied conditions a text book of rheumatology. William & Wilkins, Baltimore, pp 1445–1454
33.
Zurück zum Zitat Jablonska S, Blaszczyk M (1999) Scleroderma overlap syndromes. Adv Exp Med Biol 455:85–92PubMed Jablonska S, Blaszczyk M (1999) Scleroderma overlap syndromes. Adv Exp Med Biol 455:85–92PubMed
34.
Zurück zum Zitat Naiperi M, Karsunky H, Zevnik B et al (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25:177–181. doi:10.1038/76032 CrossRef Naiperi M, Karsunky H, Zevnik B et al (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25:177–181. doi:10.​1038/​76032 CrossRef
35.
Zurück zum Zitat Shin HD, Park BL, Kim LH et al (2004) Common DNase I polymorphism associated with autoantibody production among systemic lupus erythematosus patients. Hum Mol Genet 13:2343–2350. doi:10.1093/hmg/ddh275 CrossRefPubMed Shin HD, Park BL, Kim LH et al (2004) Common DNase I polymorphism associated with autoantibody production among systemic lupus erythematosus patients. Hum Mol Genet 13:2343–2350. doi:10.​1093/​hmg/​ddh275 CrossRefPubMed
Metadaten
Titel
DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects
verfasst von
Salima Belguith-Maalej
Hassen Hadj-Kacem
Neila Kaddour
Zouhir Bahloul
Hammadi Ayadi
Publikationsdatum
01.11.2009
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 1/2009
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0917-4

Weitere Artikel der Ausgabe 1/2009

Rheumatology International 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.